Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The retinal macular lipid membrane refers to the specialized lipid bilayers found within the macula, specifically in the photoreceptor outer segments (POS) and the retinal pigment epithelium (RPE). These membranes are uniquely enriched with long-chain polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA), which are essential for the high fluidity and rapid signal transduction required for phototransduction (Source: PubMed, PMID: 15577177). However, this high PUFA content makes the macula highly susceptible to oxidative stress and the accumulation of toxic metabolic byproducts like lipofuscin (A2E), which are hallmarks of age-related macular degeneration (AMD) and Stargardt disease (Source: NIH, National Eye Institute). Therapeutic strategies targeting these membranes focus on preserving structural integrity and preventing oxidative damage through the administration of macular pigments (lutein and zeaxanthin) or modifying the visual cycle to reduce the formation of membrane-disrupting aggregates. For instance, gildeuretinol (ALK-001) is a deuterated form of vitamin A designed to slow the dimerization of retinal into toxic lipofuscin within these membranes (Source: Alkeus Pharmaceuticals). Additionally, lipid-lowering agents like fenofibrate are being explored for their ability to regulate lipid metabolism and protect the RPE from lipid-induced stress (Source: ARVO Journals). Maintaining the integrity and biochemical composition of these membranes is crucial for preventing the progressive degeneration of macular tissues and preserving central vision.
Stabilization of membrane fluidity, antioxidant scavenging of reactive oxygen species, filtration of high-energy blue light, and inhibition of toxic bis-retinoid (lipofuscin) formation within the lipid bilayer.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal macular lipid membrane.